A Phase 1b/2 trial of tazemetostat in combination with atezolizumab (TECENTRIQ) for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC)

Trial Profile

A Phase 1b/2 trial of tazemetostat in combination with atezolizumab (TECENTRIQ) for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Tazemetostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 04 Aug 2017 According to an Epizyme media release, the company expects to begin enrolment in this study by the end of 2017.
    • 04 Jul 2017 New trial record
    • 26 Jun 2017 According to an Epizyme media release, this trial is expected to be initiated by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top